FTC clears BioArctic’s deal with BMS
Sweden’s BioArctic (Nasdaq: BIOA B) today revealed that the US Federal Trade Commission (FTC) has cleared the deal with Bristol Myers Squibb (NYSE: BMY) to out-license to the US pharma major its pyroglutamate-amyloid-beta (PyroGlu-Aβ) antibody program. Closing of the agreement has been completed and BioArctic will receive an upfront payment of $100 million.
On December 19, 2024, BioArctic announced that it had entered into a global license agreement with BMS under which the latter will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide.
The agreement was subject to filing and clearance under US Antitrust legislation (the Hart-Scott-Rodino Antitrust Improvements Act of 1976), a condition which has been fulfilled, and the transaction has now closed. The finalization of the agreement triggers an upfront payment of $100 million to BioArctic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze